(-0.04%) 5 305.77 points
(0.08%) 39 839 points
(-0.22%) 16 759 points
(-0.86%) $79.11
(-2.33%) $2.69
(-0.26%) $2 432.10
(-0.20%) $32.36
(0.46%) $1 068.60
(0.11%) $0.922
(-0.27%) $10.67
(-0.04%) $0.787
(-0.21%) $90.48
@ $2.43
发出时间: 13 Feb 2024 @ 04:26
回报率: -21.73%
上一信号: Feb 7 - 03:26
上一信号:
回报率: 0.00 %
Live Chart Being Loaded With Signals
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States...
Stats | |
---|---|
今日成交量 | 4 655.00 |
平均成交量 | 1.48M |
市值 | 5.44M |
EPS | $0 ( 2024-05-20 ) |
下一个收益日期 | ( $-0.980 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.220 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-01 | Young David | Buy | 1 675 | Common Stock |
2024-01-01 | Young David | Sell | 518 | Common Stock |
2024-01-01 | Young David | Sell | 1 675 | Restricted Stock Units |
2024-01-01 | Stanker James H | Sell | 1 675 | Restricted Stock Units |
2024-01-01 | Stanker James H | Buy | 1 675 | Common Stock |
INSIDER POWER |
---|
80.51 |
Last 99 transactions |
Buy: 3 005 145 | Sell: 402 801 |
Processa Pharmaceuticals, 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-222.00 (0.00 %) |
EPS: | $-0.850 |
FY | 2023 |
营收: | $0 |
毛利润: | $-222.00 (0.00 %) |
EPS: | $-0.850 |
FY | 2022 |
营收: | $0 |
毛利润: | $-27.53M (0.00 %) |
EPS: | $-68.10 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.750 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Processa Pharmaceuticals,
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。